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A B S T R A C T
Introduction: Traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) are risk factors for early
onset of Alzheimer's disease (AD) and may accelerate the progression rate of AD pathology. As amyloid-beta (Aβ)
plaques are a hallmark of AD pathology, we hypothesized that TBI and PTSD might increase Aβ accumulation in
the brain.
Methods: We examined PET and neuropsychological data from Vietnam War veterans compiled by the US
Department of Defense Alzheimer's Disease Neuroimaging Initiative, to examine the spatial distribution of Aβ in
male veterans' who had experienced a TBI and/or developed PTSD. Subjects were classiﬁed into controls, TBI
only, PTSD only, and TBI with PTSD (TBI_PTSD) groups and data were analyzed using both voxel-based and ROI-
based approaches.
Results: Compared to controls, all three clinical groups showed a pattern of mainly increased referenced stan-
dard uptake values (SUVR) for the amyloid tracer [18F]-AV45 PET, with rank order
PTSD > TBI_PTSD > TBI > Control, and same rank order was seen in the deﬁcits of cognitive functions. SUVR
increase was observed in widespread cortical regions of the PTSD group; in white matter of the TBI_PTSD group;
and cerebellum and precuneus area of the TBI group, in contrast with controls. The [18F]-AV45 SUVR correlated
negatively with cerebrospinal ﬂuid (CSF) amyloid levels and positively with the CSF tau concentrations.
Conclusion: These results suggest that both TBI and PTSD are substantial risk factors for cognition decline and
increased Aβ deposition resembling that in AD. In addition, both PTSD and TBI_PTSD have a diﬀerent pathways
of Aβ accumulation.
1. Introduction
Post-traumatic stress disorder (PTSD) is an anxiety disorder occur-
ring in response to traumatic stress such as may occur in combat. A
retrospective study of t veterans with PTSD showed a two-fold higher
risk of developing dementia compared to veterans without PTSD even
after adjusting for other comorbidities (Yaﬀe et al., 2010), and PTSD
increases the risk for dementia and Alzheimer's disease (AD) (Cohen
et al., 2013; Finfer and Cohen, 2000; Wang et al., 2010; Yaﬀe et al.,
2010b). Traumatic brain injury (TBI) is one of the leading causes of
death and disability in the young population (Finfer and Cohen, 2000).
Survivors of TBI often suﬀer from permanent neurological and cogni-
tive deﬁcits, with increased risk for developing AD. There is consider-
able comorbidity of PTSD with TBI, especially among war veterans
(Alway et al., 2016; Amen et al., 2015), which raises the question of
whether the two conditions interact regarding the risk of neurodegen-
erative changes and dementia.
The most common form of dementia is AD, which is characterized
by brain pathology consisting of extracellular Aβ plaques, intraneuronal
tangles of phosphorylated tau protein, synapse loss, and neuronal loss
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(Hardy, 2002; Kerbler et al., 2015).The transition from mild cognitive
impairment (MCI) to AD can be monitored in PET studies with amyloid-
beta (Aβ) ligands such as [11C]-PiB and [18F]-AV45 (Florbetapir)
(Nemmi et al., 2014; Saint-Aubert et al., 2013). Increased Aβ plaque
deposition has been reported in post mortem examination of brain from
TBI victims (Johnson et al., 2012), and is now being documented in PET
studies of TBI patients. For example, in a [11C]-PiB PET study of TBI
patients, researchers found increased Aβ deposition in the posterior
cingulate cortex, cerebellum and striatum (Scott et al., 2016), regions
that extensively overlapped with the pattern of Aβ deposition found in
AD brain. Indeed, Aβ plaques have been observed in about one third of
TBI subjects (Johnson et al., 2012, 2010), irrespective of patient's age,
suggesting that TBI is a causative factor in Aβ deposition (Uryu et al.,
2007). Interestingly, Aβ plaques were seen shortly after an injury event
(Ikonomovic et al., 2004) but not in long term survivors of TBI (Chen
et al., 2009), suggesting that enhanced amyloid clearance mechanisms
may compensate for an acute injury-related accumulation.
There is scant documentation of the relationship between PTSD
with amyloid deposition. Studies in rodent models of PTSD due to
chronic stress indicated accelerated amyloid plaque formation and Aβ
release (Rothman et al., 2012). To investigate this phenomenon, the
Department of Defense (DOD) funded a component of the Alzheimer's
Disease Neuroimaging Initiative (ADNI) speciﬁcally to investigate
amyloid burden, cognitive changes, and brain structural/functional
changes in Vietnam War veterans. A preliminary analysis of data from
the DOD-ADNI consortium showed worse global cognitive function in
Vietnam War veterans with PTSD, but did not reveal the expected and
hypothesized increase in Aβ burden when considering the entire cere-
bral cortex as a single volume of interest (Weiner et al., 2017). We
hypothesized that the earlier analysis of this data may have missed focal
alterations in Aβ deposition in the subgroup of long-term PTSD survi-
vors, and furthermore that spatial mapping of Aβ might distinguish the
PTSD group from groups with TBI and cases of mixed TBI and PTSD
(TBI_PTSD). To test these linked hypothesis, we undertook a voxel-
based re-analysis of the DOD-ADNI data sets, and made a statistical
comparison of the PTSD, TBI and TBI_PTSD group ﬁndings contrasted
with demographically matched control material.
2. Materials and method
2.1. Study subjects
Data used in the preparation of this article were obtained from the
DOD-ADNI as part of ADNI database (adni.loni.usc.edu) which was
launched in 2003 as a public-private partnership, led by Principal
Investigator Michael W. Weiner, MD. The primary goal of ADNI has
been to test whether serial MRI, PET, other biological markers, and
clinical and neuropsychological assessment can be combined to mea-
sure the mild cognitive impairment progression and early onset of AD.
DOD-ADNI aimed at investigating the eﬀect of TBI and PTSD on brain
function and structure, and identiﬁes the risk for progression to AD. For
up-to-date information, see www.adni-info.org.
Ethical approval to use the de-identiﬁed data was also obtained
from the Human Research Ethics Committee of the University of
Queensland, Australia (IRB number #2017000630). Data were col-
lected as part of a multicenter trial run by the DOD-ADNI initiative. In
addition, as part of DOD-ADNI, all subjects signed an informed consent
form including all the experimental procedures.
A total of 190 male VietnamWar veterans (age= 74.8 ± 6.2 years)
were recruited by the DOD-ADNI study. After a rigorous quality control
of the PET imaging data for motion, attenuation and other image arti-
facts, there remained 166 subjects (age 73.7 ± 6.2 years). These in-
dividuals belonged to one of four clinical groups: healthy controls
without psychiatric or neurological illness (n= 57 subjects), PTSD
without TBI (PTSD; n=57 subjects), PTSD with TBI (TBI_PTSD; n=29
subjects), and moderate/severe TBI without PTSD (TBI; n= 21 sub-
jects), as shown in Fig. 1. We excluded from our study a total of 17 male
veterans of non-Caucasian ethnicity, as shown in Fig. 1. Here, our in-
tention was to eliminate confounds due to possible ethnicity-related
diﬀerences in brain volume (Isamah et al., 2010) and grey matter in-
tegrity (Liu et al., 2015), as shown in Fig. 1. All subjects had served
during the Vietnam War with or without documented history of mod-
erate-severe non-penetrating TBI related to military service, and with/
without evidence of PTSD identiﬁed using the Structured Diagnostic
Interview for DSM-V & Clinician Administered PTSD Scale (CAPS) with
a cut-oﬀ score of 30 (refer to Fig. 1. for further details on the study
population).
Fig. 1. Final groups and clinically classiﬁed subjects. Subjects were classiﬁed into four diﬀerent groups including healthy controls, traumatic brain injury (TBI), post-
traumatic stress disorder (PTSD), and TBI subjects with PTSD (TBI_PTSD).
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2.2. Study design
The study is a multimodality non-randomized natural history non-
intervention study. DOD-ADNI recruited Vietnam War Veterans, iden-
tiﬁed from the Veteran Aﬀairs Compensation and Pension records, to
undergo a multitude of assessments including magnetic resonance
imaging (MRI), amyloid PET using [18F]-AV45 (Forbetapir), cognitive
testing, cerebral spinal ﬂuid biomarkers of tau, phosphorylated-tau, Aβ,
and blood sampling for analysis of genetic factors associated with a
history of TBI or ongoing PTSD.
2.3. Neuropsychological assessment
All participants underwent a battery of cognitive and neu-
ropsychological assessments including Montreal Cognitive Assessment
(MoCA) (Nasreddine et al., 2005), Everyday Cognition (ECog) (Farias
et al., 2008), Mini-Mental State Exam (MMSE) (Folstein et al., 1975),
Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) (Skinner
et al., 2012), American National Adult Reading Test (AMEreading)
(Spreen and Strauss, 1998), Clinical Dementia Rating (CDR) (Morris,
1993), Functional Assessment Questionnaire (Ito et al., 2012), Combat
Exposure Scale (CES), and Geriatric Depression Scale (GDtotal).
2.4. Cerebrospinal ﬂuid (CSF) sample collection and analysis
CSF samples were collected through lumbar puncture and were
analyzed with established ADNI methods (Aisen et al., 2010) to mea-
sure levels of Aβ42, total tau, and phosphorylated tau at threonine 181
(p-tau181) using the validated Luminex xMAP multiplex immunoassay
platform.
2.5. MRI and PET imaging
2.5.1. MRI acquisition
All procedures were standardized across all sites for the conduct and
acquisition of the data using qualiﬁed ADNI systems. T1-weighted
anatomical image was acquired with a Spoiled Gradient Recalled Echo
sequence (TE/TI/FA/BW1=Min/400/11/31.25, sagittal plane, matrix
size 256×256×200 and resolution 1× 1×1.2mm).
2.5.2. PET acquisition
Amyloid PET images were acquired using [18F]-AV45, a radio-
pharmaceutical that binds to amyloid plaques. A dose of 370MBq
(10mCi ± 10%) bolus injection of [18F]-AV45 was administered to
each subject followed by resting-uptake phase of 50min, whereupon
subjects were positioned within the tomograph for acquisition of four
emission frames of 5min each. PET images were 3D reconstructed using
Iterative (fully 3D Iteration; four iterations; 20 subsets) with a grid of
128×128, FOV: 256×256mm, slice thickness: 3.27mm.
2.6. Image preprocessing and analysis
Data pre-processing and analysis were performed using FMRIB's
Software Library (Jenkinson et al., 2012) (FSL 5.0.9, Analysis Group,
FMRIB, Oxford, UK, 2012) and Freesurfer (Fischl, 2012) (Martinos
Center for Biomedical Imaging, Laboratory for Computational Neuroi-
maging, Boston, United States).
2.6.1. MRI image processing
MR images were reoriented to match with the Montreal
Neurological Institute (MNI) structural template (Grabner et al., 2006)
and MRI image were segmented using the RECON-ALL function from
Freesurfer. The cerebellum of each subject was segmented for the pre-
processing of the PET data. Structural data were then resampled to
1.5 mm isotropic resolution and co-registered to the MNI-152 template
using nonlinear co-registration tool (FNIRT) (Andersson et al., 2007).
2.6.2. PET pre-processing
The four emission frames were co-registered to each other to correct
for head motion, and standard uptake value (SUV) was calculated voxel
wise. The SUV images were reoriented to the FSL orientation and re-
sampled to 1.5×1.5×1.5mm3 to match with the MNI template's re-
solution. The SUV maps were coregistered to each subject's T1-
weighted image using a linear co-registration tool (Flirt) (Jenkinson
et al., 2002) to match the subject's SUV map with the individual
structural MRI image. To compute the referenced SUV (SUVR) maps,
we followed the conventional practice in in scaling the entire brain
signal intensity to the mean activity in the individual cerebellum
(WH+GM), which was segmented on the MRI. This is a standard ap-
proach for transforming SUV maps to normalized SUVR maps for this
PET tracer (Scott et al., 2016; Weiner et al., 2017). In particular, we co-
registered the SUV maps of each individual to the corresponding seg-
mented T1 structural MRI data, and then extracted the cerebellum SUV
value, which was used to calculate parametric SUVR maps of each in-
dividual.
The SUVR maps were co-registered to the MNI template using both
the transformation matrix and warp ﬁles calculated for the T1-MRI
registration to the MNI template. The registered SUVR maps were
smoothed using a Gaussian ﬁlter with a common isotropic resolution of
6mm and amyloid positivity was deﬁned according to the threshold of
SUVR>1.1 (Landau et al., 2012).
2.7. Statistical analysis
Neuropsychological data were analyzed using RStudio 3.3.3. Since
non-normality was present in the data, we performed nonparametric
tests using Kruskal-Wallis tests to examine group diﬀerences, followed
by performance of pairwise comparisons using Conover-Iman tests and
Spearman's rho to examine the correlations between measurements.
Statistical signiﬁcance was set at α=0.05. Correlations between CSF β-
amyloid and tau levels, and SUVR of the parietal, temporal, frontal and
cingulate cortices were calculated for each group using Spearman's rho
correlation test.
PET SUVR maps were used to generate group's average maps using
the one sample t-test with FSL-randomize (Winkler et al., 2014). To
contrast the amyloid accumulation in clinical groups versus the control
group, we used an unpaired 2-sample t-test to generate voxel-based
diﬀerence maps using FSL-randomize nonparametric permutation tests
with 1000 permutations. Results were corrected using cluster-based
correction through threshold-free cluster enhancement (p < 0.05,
cluster volume > 40 voxels).
To investigate the group diﬀerences in brain regions by VOI ana-
lysis, individuals' SUVR values were extracted from a set of templates
including frontal, cingulate, parietal, temporal cortices, anterior cin-
gulate cortex, middle temporal gyrus, inferior parietal lobule, medial
frontal gyrus and precuneus, all deﬁned in the individual structure MRI
data. The group VOI data were analyzed using unpaired t-test to iden-
tify regions with signiﬁcant diﬀerences between groups, with
Bonferroni correction (p < 0.05). Correlations between CSF amyloid
and tau, and SUVR of the parietal, temporal, frontal and cingulate
cortices were calculated for each group using Pearson's r-correlation
test (p < 0.05).
3. Results
3.1. Clinical outcome and TBI and/or PTSD groups
The mean current-CAPS scores were signiﬁcantly higher in the PTSD
group in contrast to TBI_PTSD (p < 0.0001), and both PTSD/TBI_PTSD
had higher mean scores than the control (p < 0.0001) and TBI group
(p < 0.00001). The mean CDRGLOBAL score was higher in PTSD
compared to controls (p < 0.00001) and TBI_PTSD (p < 0.001), sug-
gesting that cognitive deﬁcits were more pronounced in both PTSD
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groups than in the TBI alone or healthy control groups. Mean CES score
was signiﬁcantly higher in the PTSD/TBI_PTSD groups compared to
controls (p < 0.00001), but only the PTSD group had signiﬁcantly
higher CES scores than did the TBI group (p < 0.01). The mean
GDtotal score was higher in PTSD/TBI_PTSD groups compared to
controls (p < 0.0001), and higher in the PTSD compared to the TBI
group (p < 0.0001). The mean total ECog scores indicated signiﬁcantly
worse cognition in the PTSD/TBI_PTSD groups compared to the control
(p < 0.0001, p < 0.001) and TBI groups (p < 0.01, p < 0.01).
Within ECog scores, the PTSD/TBI_PTSD groups showed worse memory
ability in contrast to healthy controls (p < 0.0001, p < 0.001), while
the PTSD group showed worse visuospatial ability (p < 0.00001);
planning and divided attention abilities were signiﬁcantly worse in
both groups compared to controls (p < 0.0001). MMSE and MoCA
scores showed no signiﬁcant diﬀerences between groups (p > 0.05).
The AMEreading scores showed that the PTSD group had signiﬁcantly
more errors compared to controls (p < 0.001). Full scale IQ test score
was signiﬁcantly lower in the PTSD group compared to healthy controls
(p < 0.01); see Table 1, Fig. 2.
3.2. Amyloid deposition in TBI and/or PTSD groups
Fig. 3. illustrates the p-statistic maps of each group mean SUVR
maps, revealing regions with signiﬁcantly elevated uptake (SUVR>
1.1) for each of the four study groups. There were sparse cortical re-
gions of higher tracer uptake in the healthy control groups, but these
regions were more extensive in the clinical groups. Interestingly, the
TBI_PTSD group showed increased mean SUVR in the white matter
while PTSD showed the highest zones of cortical SUVR relative to
controls, see Fig. 3.
3.3. Group diﬀerences in amyloid deposition between TBI and/or PTSD
groups
Signiﬁcant diﬀerences in [18F]-AV45 SUVR in the three clinical
groups compared to the controls are represented in Fig. 4. TBI subjects
had signiﬁcantly higher [18F]-AV45 SUVR in the cerebellar tonsil
(1.32 ± 0.21 versus 1.12 ± 0.25; p=0.038) and precuneus
(1.25 ± 0.21 versus 0.87 ± 0.20; p=0.029) compared to controls,
while SUVR was lower in ventrolateral prefrontal cortex (1.12 ± 0.2
versus1.2 ± 0.19; p=0.041); see Fig. 4A and Fig 5.
The TBI_PTSD group showed increased [18F]-AV45 SUVR relative to
controls, which was more localized to the white matter (1.6 ± 0.31
versus 1.32 ± 0.34; p=0.027) especially in the corpus callosum
(1.84 ± 0.5 versus 1.52 ± 0.5; p=0.009), cingulate cortex
Table 1
Demographics and Neuropsychological performance by groups.
Healthy TBI TBI_PTSD PTSD
Mean (STD) Mean (STD) Mean (STD) Mean (STD)
Number of
subjects
57 21 31 57
Number of CSF 27 9 6 23
Age 70.9 (6.01) 67.9 (4.4) 68.7 (3.1) 67.8 (3.7)
Males (%) 100 100 100 100
ADAS-Cog 10.8 (4.58) 9.4 (3.6) 11 (5.2) 12.8 (3.9)
CAPS Current 2.22 (4.14) 7.36 (6.21) 39.08 (11.96) 56.64 (11.48)
CDR 0.05 (0.2) 0.33 (0.56) 0.47 (0.24) 0.21 (0.27)
CES 10.89 (10.2) 17 (10.35) 24.4 (10.12) 24.13 (8.88)
GDtotal 0.712 (0.91) 1.41 (1.91) 2.96 (2.6) 4 (2.82)
ECog memory 13.31 (5.25) 13.06
(5.47)
17.22 (5.77) 16.06 (5.67)
ECog language 13.12 (5.86) 12.53
(5.61)
15.93 (6.43) 17.11 (7.25)
ECog visspat 7.68 (1.24) 8.82 (3.52) 9.48 (3.98) 9.89 (3.72)
ECog plan 5.88 (1.5) 7.06 (3.54) 7.96 (3.19) 7.7 (2.76)
ECog divatt 5.66 (2.09) 6.53 (2.83) 8.22 (3.75) 7.85 (3.29)
ECog total 54.61
(15.08)
57.82
(22.97)
70.74 (23.72) 69.74 (23.35)
MMSE 28.75 (1.28) 28.94
(1.03)
28.22 (1.53) 28.09 (1.66)
MOCA 24.86 (2.76) 25.18
(3.36)
23.41 (2.89) 23.49 (3.84)
AMEreading 12.73 (8.11) 14.41
(8.43)
14.22 (10.77) 18.55 (11.27)
FSIQ 117.2 (6.65) 115.7
(6.880)
115.9 (8.93) 112.4 (9.28)
MoCA, Montreal Cognitive Assessment; ECog, Everyday Cognition; CAPS,
Clinician-Administered PTSD Scale; MMSE, Mini-Mental State Exam; ADAS-
COG, Alzheimer's Disease Assessment Scale-Cognitive; CDR, Clinical Dementia
Rating; GDtotal, Geriatric Depression Scale; AMEreading, American Reading
test; FSIQ, Full Scale Intelligence Quotient; CES, Center for Epidemiologic
Studies Depression Scale.
Fig. 2. Charts showing the Neurophysiological and clinical outcomes diﬀerences. Signiﬁcant diﬀerences were identiﬁed with p < 0.01. CAPS, Clinician-
Administered PTSD Scale; CES, Center for Epidemiologic Studies Depression Scale; CDR, Clinical Dementia Rating; ECOGtotal, total score for Everyday cognition;
GDtotal, Geriatric Depression Scale; FSIQ, Full Scale Intelligence Quotient; TBI, traumatic brain injury; PTSD, post-traumatic stress disorder; TBI_PTSD, TBI subjects
who developed PTSD.
A.Z. Mohamed et al. NeuroImage: Clinical 19 (2018) 716–726
719
(1.52 ± 0.36 versus 1.31 ± 0.4; p=0.01), the middle temporal gyrus
(1.25 ± 0.185 versus 1.12 ± 0.26; p=0.048), while uptake was
signiﬁcantly lower comparted to controls in the middle frontal gyrus
(1.21 ± 0.35 versus 1.48 ± 0.21; p=0.032), superior temporal gyrus
(1.5 ± 0.28 versus 1.7 ± 0.19; p=0.028), and inferior parietal
cortex (1.2 ± 0.21 versus 1.42 ± 0.34; p=0.031); see Fig. 4B and Fig
5.
PTSD group had signiﬁcantly higher [18F]-AV45 SUVR in various
cortical areas including the prefrontal cortex (1.43 ± 0.2 versus
0.93 ± 0.41; p=0.041), orbital gyrus (1.52 ± 0.29 versus
1.18 ± 0.21; p=0.034), superior, middle and inferior temporal gyrus
(1.2 ± 0.23 versus 1.21 ± 0.24; p=0.032), hippocampus
(1.56 ± 0.3 versus 1.3 ± 0.41; p=0.031), middle and inferior occi-
pital gyrus (1.52 ± 0.18 versus 1.3 ± 0.21; p=0.021), posterior
cingulate gyrus (1.2 ± 0.12 versus 0.92 ± 0.41; p=0.05), and sup-
plementary motor area (1.52 ± 0.32 versus 1.3 ± 0.31; p=0.04), all
compared to controls; see Fig. 4C and Fig 5.
3.4. Correlation between amyloid tracer uptake in brain and amyloid and
tau levels in CSF
Fig. 6 shows the correlations between [18F]-AV45 SUVR in four
ROIs with the CSF amyloid concentrations. Healthy controls showed
negative correlation in frontal (r2= 0.15; p=0.046), parietal
(r2= 0.152; p=0.045), and cingulate (r2= 0.16; p=0.036) cortices.
Interestingly we observed signiﬁcant negative correlations in the TBI-
alone group in frontal (r2= 0.22; p=0.03), parietal (r2= 0.27;
p=0.036), cingulate (r2= 0.25; p=0.04), and temporal cortex
(r2=0.3; p=0.033), and also in the TBI_PTSD group for frontal
(r2= 0.51; p=0.026), parietal (r2= 0.69; p=0.03), cingulate
(r2=0.36; p=0.02), and temporal cortex (r2=0.13; p=0.04); see
Fig. 6 and Table 2.
Fig. 3. [18F]-AV45 SUVR average maps for each group showing region with amyloid positive uptake in the brain for diﬀerent groups. Healthy controls showed the
lowest uptake (A), while clinical groups showed more uptake in TBI, with higher in TBI_PTSD and the highest SUVR values in PTSD.
Fig. 4. Groups comparisons of [18F]-AV45 SUVR between clinical groups and healthy group. A. TBI vs. healthy controls, B. TBI_PTSD vs. healthy control, and C. PTSD
vs. healthy control. Red-yellow means higher means higher amyloid in clinical groups while blue-green means higher amyloid in healthy controls. Diﬀerence maps
were calculated using unpaired t-test amyloid in clinical groups and blue and green test and results were corrected using cluster-based correction (p < 0.05,
Z > 2.3, cluster> 40 voxels). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 7 shows the correlations between individual [18F]-AV45 SUVR
in four cortical ROIs with CSF tau-protein concentrations. Signiﬁcant
positive correlations were observed in the healthy control group within
frontal (r2= 0.16; p=0.027) and temporal cortex (r2= 0.24;
p=0.01). Signiﬁcant positive correlations were observed in the TBI
group within frontal (r2= 0.36; p=0.043), cingulate (r2= 0.3;
p=0.036), parietal (r2= 0.33; p=0.029), and temporal cortex
(r2= 0.3; p=0.01). There were no such signiﬁcant correlations in the
PTSD or TBI_PTSD groups; see Fig. 7 and Table 2.
4. Discussion
We used [18F]-AV45 PET imaging to investigate Aβ deposition in
brain of Vietnam War veterans, seeking in particular to identify eﬀects
of PTSD alone or in association with TBI on this neuropathological
marker. Earlier analysis of the data, considered the whole cerebral
cortex as single ROI, had failed to reveal evidence for amyloidosis in
brain of the veterans with PTSD and/or TBI (Weiner et al., 2017), but
we felt that a voxel-wise statistical comparison might reveal regional
patterns of amyloid accumulation not evident in that study. Indeed, we
found notable accumulations of amyloid in the frontal, occipital and
temporal lobes of PTSD suﬀerers with signiﬁcant cognitive dysfunction,
and in the white matter of TBI_PTSD group. Furthermore, we found
correlation between amyloid PET results and CSF markers of neuro-
pathology in the TBI and TBI_PTSD groups.
4.1. Neurocognition as a marker of progression to AD
A broad battery of neuropsychological tests had been collected to
assess cognitive function in these Vietnam war veterans. The PTSD
Fig. 5. Shows the referenced standard uptake values (SUVR) for the ﬁve brain lobes. It shows signiﬁcant SUVR diﬀerences between groups in the ﬁve VOIs, i.e.
frontal, cingulate, parietal, occipital and temporal lobes.
Table 2
Correlations between amyloid in the brain and cerebrospinal ﬂuid concentrations of amyloid and tau.
Healthy TBI TBI_PTSD PTSD
R2 (p) R2 (p) R2 (p) R2 (p)
CSF Amyloid Frontal 0.15 (p=0.046) 0.22 (p=0.03) 0.51 (p=0.026) 0.05 (p=0.85)
Parietal 0.152 (p=0.046) 0.27 (p=0.036) 0.69 (p=0.03) 0 (p=0.3)
Cingulate 0.16 (p=0.036) 0.25 (p=0.04) 0.36 (p=0.02) 0.09 (p=0.67)
Temporal 0.02 (p=0.8) 0.3 (p=0.033) 0.13 (p=0.04) 0.01(p=0.7)
Frontal 0.16 (p=0.27) 0.36 (p=0.043) 0 (p=0.9) 0.03 (p=0.7)
CSF Tau Parietal 0.08 (p=0.12) 0.33 (p=0.029) 0 (p=0.86) 0 (p=0.2)
Cingulate 0.09 (p=0.3) 0.3 (p=0.036) 0.09 (p=0.6) 0.12 (p=0.4)
Temporal 0.24 (p=0.01) 0.3 (p=0.01) 0.14 (p=0.34) 0 (p=0.3)
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patients exhibited the worst cognitive performance on all assessments,
followed by TBI_PTSD subjects, whereas cognitive scores in the TBI and
control groups did not diﬀer (Fig. 2).
TBI is a risk factor for PTSD (Xue et al., 2015), and both bring high
risk for developing dementia later in life (Alway et al., 2016; Ruigrok
et al., 2014). Indeed, 63% of our TBI participants had developed PTSD
with a life CAPS score > 40 and current CAPS score > 30. This is
consistent with previous ﬁndings that veterans with deployment-related
TBI had more severe post-deployment PTSD symptoms (Yurgil et al.,
2014), and that most TBI patients also suﬀer from PTSD (Yurgil et al.,
2014). The causal link between TBI and PTSD may relate to the physical
and cognitive impairment arising from the TBI, both of which increase
PTSD prevalence (Koren et al., 2005; Xue et al., 2015). Alternately,
emotional trauma arising in proportion to severity of the TBI may be
the driver for developing PTSD (Yurgil et al., 2014).
We observed reduced cognitive function in both the PTSD and
TBI_PTSD groups for all sub-categories of the ECog scale. While prior
studies have not used ECog to investigate cognitive performance in
relation to daily life of PTSD patients, several studies report lower
cognitive function among PTSD patients (Cohen et al., 2013; Greenberg
et al., 2014; Russman Block et al., 2017). The present changes suggest
that altered brain structure or function following TBI may be associated
with a risk for developing PTSD, neurodegenerative disease, or cogni-
tive impairment.
In a recent study, Li et al. showed that age at the time of TBI in-
ﬂuences ECog scores, with signiﬁcantly higher ECog scores in all do-
mains among patients experiencing their TBI during childhood (Li
et al., 2017). We suppose that TBI in young adulthood may likewise
have propagated to more severe cognitive eﬀects in the present group of
veterans. The mean GDtotal score was higher in PTSD and TBI_PTSD
groups compared to TBI alone and control groups, consistent with the
previous report (Marmar et al., 2015), which showed that 30% percent
of PTSD patients had depression symptoms or depressive disorders
40 years after their Vietnam war service. The low incidence of beha-
vioral and substance abuse disorders in our PTSD patients matches the
ﬁndings of a previous study, where incidence of illicit drug use declined
from 30% in 1972 to only 8% in 1996 (Balan et al., 2013).
4.2. Amyloid PET ﬁndings in the three clinical groups
TBI is now understood to provoke an acute increase of amyloid
precursor protein (APP), the source for amyloid plaque formation, in
response to axonal injury (Hefter and Draguhn, 2017). Diﬀusion tensor
imaging (DTI) consistently shows white matter changes due to axonal
injury and tract degradation post-TBI (Kou et al., 2010). The present
TBI group showed clusters of increased Aβ deposition mainly in the
cerebellum and precuneus regions (Fig. 4), rather matching the pattern
of increased [11C]-PiB binding reported in TBI patients scanned
1–17 years after injury (Scott et al., 2016). Others reported Aβ plaque
evident to PET and histopathology examination performed directly
after the TBI (Ikonomovic et al., 2004; Roberts et al., 1994), and in-
creased [11C]-PiB binding in cortex but not white matter of TBI patients
scanned within one year of injury (Hong et al., 2014). However, pre-
sumed short term increases in plaque density were not evident to his-
topathological examination at some three years after the injury, despite
an ongoing elevation of APP in the white matter (Chen et al., 2009).
This implies that transient Aβ plaques can be substantially cleared in
the years after TBI. In a post mortem study of long term TBI survivors,
approximately one third had increased Aβ plaques, leading the authors
to conclude that this subset of TBI survivors were at increased risk for
developing AD (Johnson et al., 2012). We suppose that the large var-
iance of [18F]-AV45 SUVR in our TBI group of only 18 subjects may
conceal some individuals with more pronounced amyloid levels.
The TBI_PTSD group showed increased [18F]-AV45 SUVR
throughout the white matter, most clearly evident in the corpus cal-
losum (Fig. 4B). Indeed, amyloid PET tracers characteristically label the
white matter, irrespective of amyloid content (Byun et al., 2017), al-
though other studies reported a subtle increase in [18F]-AV45 SUVR in
white matter of AD patients compared to healthy controls, (Nemmi
et al., 2014). Therefore we cautiously attribute the present ﬁndings in
the TBI_PTSD group to indicate Aβ accumulation in white matter. In-
deed, there is concurrence of Aβ deposition and altered DTI in white
matter of humans with TBI (Bendlin et al., 2012), and, a DTI study
reported that white matter was more compromised in TBI_PTSD pa-
tients than in those with TBI alone (Lepage et al., 2017). Although not
directly comparable to studies of recent injuries, we suppose that con-
current PTSD may have interfered with the recovery of axonal injury
upon TBI in these veterans. In addition, we speculate that the history of
TBI 40 years earlier initiated an Aβ pathology similar to that of AD,
although it remains to be seen if this TBI cohort will progress to AD. To
determine if the PET tracer used in this study could accurately predict
the presence of β-amyloid in the brain at autopsy, we looked at the
literature and found it does (Clark et al., 2011; Ikonomovic et al.,
2016). In the study performed by Clark et al., 28 of a series of 29 AD
patients who underwent Florbetapir-PET one year antimortem showed
concord between PET and histopathological ﬁndings for β-amyloid
positivity or negativity (Clark et al., 2011). In addition, Ikonomovic
et al. showed that 90% of PET assessments of AD patients accurately
reﬂected the amyloid plaque burden revealed from postmortem his-
tology (Ikonomovic et al., 2016).
Veterans with PTSD have a two-fold increased risk for developing
AD (Yaﬀe et al., 2010), but few studies have investigated the presence
of Aβ in human PTSD. In animal models of PTSD entailing chronically
elevated stress, the formation rate of amyloid plaques increased (Devi
et al., 2010; Justice et al., 2015; Rothman et al., 2012). Amyloid plaque
deposition in AD has been a long-standing topic. Several imaging stu-
dies have demonstrated that Aβ feature of the AD brain; Johnson et al
compared 45 AD patients in contrast to 79 healthy controls and showed
that the AD group showed higher [18F]-AV45 uptake in the precuneus,
frontal, temporal, parietal, and anterior and posterior cingulate cortices
(Johnson et al., 2013), with same pattern shown by Scott et al. (Scott
et al., 2016), and supported by review reports (Chételat et al., 2013;
Morris et al., 2016; Vlassenko et al., 2012). Interestingly, it has been
shown that a history of PTSD symptoms increases the risk for devel-
oping AD (Qureshi et al., 2010; Yaﬀe et al., 2010b). Our results reﬂect
similar ﬁndings where increased levels of Aβ are seen frontal, temporal,
parietal, and anterior and posterior cingulate cortices in the brain of
PTSD subjects that overlap with amyloid increase correspondent to AD
(see Table 3). This may suggest that amyloid could be a possible link
between PTSD and AD supported by the overlapping etiologies for
PTSD and AD. One possible cause for amyloid presence could be the
stress-related changes in the hypothalamic–pituitary–adrenal (HPA)
axis (Morris et al., 2012). Indeed, PTSD and AD are both characterized
by volumetric loss in the hippocampus in association with cognitive
decline (Justice et al., 2015b; Tsolaki et al., 2009). The hippocampus is
a particularly plastic and vulnerable region of the brain (McEwen,
Table 3
Regions with increased β-amyloid with similar spatial distribution of β-amyloid
both in TBI, PTSD and AD.
This table reports present results and ﬁndings of Scott et al. (2016).
TBI (Scott et al.,
2016)
PTSD AD (Scott et al.,
2016)
Cerebellum yes Not reported Less than TBI
Cingulate Not reported Reported Reported
Pre-frontal Cortex Not reported Reported Reported
Medial prefrontal
cortex
Not reported Reported Reported
Temporal Cortex Not reported Reported Reported
Parietal cortex Not reported Reported Reported
Precuneus Reported Not reported Reported
Occipital Not Reported Reported Not reported
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1999). Several MRI studies of PTSD patients have shown decreased
volumes of hippocampus (Lindauer et al., 2005; Schuﬀ et al., 2008; van
Rooij et al., 2015), anterior cingulate cortex (Schuﬀ et al., 2008;
Sekiguchi et al., 2013), and prefrontal structures (Woodward et al.,
2009). Smaller hippocampal volumes have been repeatedly associated
with development (Gilbertson et al., 2002) and persistence (van Rooij
et al., 2015) of PTSD symptoms. In contrast, some studies showed no
volumetric increases in hippocampus even after full recovery from
PTSD symptoms (Lindauer et al., 2005; van Rooij et al., 2015). Thus,
the causal relation between PTSD and volumetric changes in PTSD
patients remains uncertain. In addition, environmental and genetic
factors can contribute importantly to the risk of developing PTSD
(Gilbertson et al., 2002; Lebois et al., 2016). In support of a HPA con-
tribution to neurodegenerative disease progression, corticosteroid le-
vels are elevated in early AD patients (Csernansky et al., 2006). In this
work, we investigated eﬀects of PTSD decades following the diagnosis,
and establish a tentative link between PTSD and β-amyloid accumula-
tion in the brain. However, diverse factors and mechanisms may have
had a direct impact on our β-amyloid ﬁndings; PTSD and AD are both
highly associated with increased neuro-inﬂammatory mediators, in-
cluding cytokines, chemokines, and other neurotoxic mediators such as
tryptase, histamine, IL-1β, TNF-α, IL-6, CCL2, IL-8, ROS, CRH, and
MMPs, any of which might contribute to neurodegeneration (Kempuraj
et al., 2017) and β-amyloid accumulation. Again, the cross-sectional
design cannot establish the causal relationship between longer duration
of PTSD and increased β-amyloid burden.
4.3. Correlation between SUVR in the brain and CSF amyloid and tau
The CSF concentration of Aβ is reduced while tau levels are elevated
in AD patients (Apostolova et al., 2010; Toledo et al., 2013), and these
typical CSF ﬁndings correlate with cerebral amyloid burden in PET
(Masters and Selkoe, 2012; Scott et al., 2016). Although we found no
signiﬁcant correlations between our CSF markers and regional [18F]-
AV45 SUVR in the PTSD and control groups, amyloid PET results in the
TBI and TBI_PTSD groups showed negative correlations with CSF Aβ
concentration and positive correlations with CSF tau concentration.
Thus, the TBI ﬁndings resemble those reported earlier for AD patients
(Apostolova et al., 2010; Toledo et al., 2013).
In severe TBI patients, increased CSF tau protein and decreased CSF
Aβ levels were predictive for poor clinical outcomes (Koerte et al.,
2015; Neselius et al., 2012; Ojo et al., 2016; Tsitsopoulos and
Marklund, 2013), whereas Neselius et al. (2012) reported CSF p-tau
increase in boxers to correlate positively with the duration after TBI. In
addition, the tau concentration in brain interstitial ﬂuid was more in-
creased in cases of focal cortical injury than in patients with axonal
injury (Marklund et al., 2009; Tsitsopoulos and Marklund, 2013). As
such, present results are consistent with a persistence of elevated tau
secretion into CSF persisting decades after TBI alone or in conjunction
with PTSD.
Present correlations between PET-SUVR with CSF markers in the
TBI and TBI_PTSD groups may suggest link between the brain β-amy-
loid and CSF amyloid accumulation, which resembles the hallmark
pathology of AD, and may thus suggest an increased risk TBI and
TBI_PTSD patients to develop AD later in life. In addition, a similar
trend of negative correlations was observed in aged healthy controls, as
shown in Fig. 6. However, the mechanisms causing the increased β-
amyloid in the brain both in the TBI and PTSD groups could diﬀer. As
shown from the results, we observed increased β-amyloid in the TBI
only group, which localized to the cerebellum and precuneus. However,
the group with TBI and PTSD showed a substantial increase of β-amy-
loid burden in the white matter, whereas the PTSD alone group showed
main increases of β-amyloid at the frontal, occipital and temporal
cortices. These diﬀerences between the three clinical groups in the
spatial distribution and maximal SUVR may explain the diﬀering re-
lationships between β-amyloid to PET and CSF concentrations of tau
and β-amyloid in all three groups.
This study is subject to limitations arising in relation to preinjury
functioning (Anderson et al., 2012) and socioeconomic status attained
in civilian life. (Hooﬁen et al., 2002). Notwithstanding, our voxel wise
reanalysis of the DOD-ADNI data reveals focally increased Aβ accu-
mulation in brain of PTSD and TBI patients, suggesting a partial overlap
with AD pathology, with increased Aβ in the occipital and temporal
cortex in PTSD patients, whereas increases are restricted to the white
Fig. 6. Shows the correlation between SUVR in diﬀerent lobes of the brain and the amyloid in cerebrospinal ﬂuid. There were signiﬁcant negative correlations
observed in both TBI and TBI_PTSD groups.
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matter in the TBI_PTSD cases. Irrespective of anatomic location, the
increased Aβ burden was associated with lower cognitive performance
in these Vietnam war veterans. The limited number of CSF samples
available is yet another limitation in making conclusive statements
about observed correlations with brain amyloid SUVR values. Despite
the limited number of subjects in the TBI and TBI_PTSD groups, we
were nonetheless able to see a signiﬁcant correlation between PET and
CSF concentrations of β-amyloid and Tau in both clinical TBI groups.
Further analysis with larger samples size will be required to conﬁrm the
patterns. The cross-sectional, non-randomized study design also adds to
these limitations and caution should be taken when making inferences
on the correlations between CSF and brain β-amyloid.
5. Conclusion
In a voxel-wise comparison of the [18F]-AV45 PET data, we detected
focally increased Aβ in cortex of the PTSD group and in white matter of
the TBI plus PTSD group. Thus, we see the ﬁrst evidence of increased Aβ
in long-term PTSD suﬀerers, suggesting that cortical pathology con-
tributes to their cognitive deﬁcits. Our voxel-wise analysis of [18F]-
AV45 revealed patterns of increased Aβ uptake that had not been dis-
cernible when examining the cerebral cortex as a single volume of in-
terest.
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